問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

China Medical University Hospital-Taipei

未分科

List

263Cases

2016-01-01 - 2018-12-26

Phase III

SB8

  • Condition/Disease

    NSCLC

  • Test Drug

    SB8

Participate Sites
7Sites

Terminated5Sites

夏德椿
China Medical University Hospital-Taipei

未分科

劉劍英
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

2016-06-01 - 2017-12-31

Phase II

A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (nal-IRI)- containing Regimens versus nab-Paclitaxel plus Gemcitabine in Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma

  • Condition/Disease

    Metastatic Pancreatic Adenocarcinoma

  • Test Drug

    MM-398

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites

2015-06-02 - 2019-11-30

Phase II

A Phase 2, multicenter, randomized, double-blind study of ficlatuzumab plus erlotinib versus placebo plus erlotinib in subjects who have previously untreated metastatic, EGFR-mutated non-small cell lung cancer (NSCLC) and BDX004 Positive Label.

  • Condition/Disease

    NSCLC

  • Test Drug

    Ficlatuzumab (AV-299),

Participate Sites
8Sites

Terminated7Sites

夏德椿
China Medical University Hospital-Taipei

未分科

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2015-05-01 - 2022-07-31

Phase III

A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy compared with Levetiracetam as Monotherapy in Pediatric Subjects With New or Recent - Onset Epilepsy.

  • Condition/Disease

    Epilepsy

  • Test Drug

    Topamax F.C. Tablets 25mg, 50mg, 100mg and Topamax Sprinkle Capsule 25mg

Participate Sites
6Sites

Terminated5Sites

周宜卿
China Medical University Hospital-Taipei

未分科

2017-04-25 - 2019-12-31

Others

An Open-label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients with Advanced Solid Tumor Malignancies

  • Condition/Disease

    solid tumor

  • Test Drug

    Sym015

Participate Sites
6Sites

Recruiting2Sites

Terminated3Sites

邱昌芳
China Medical University Hospital-Taipei

未分科

2016-11-01 - 2022-02-28

Phase III

A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer

  • Condition/Disease

    Metastatic Colorectal Cancer

  • Test Drug

    LGX818 ( Encorafenib) , MEK162( Binimetinib)

Participate Sites
8Sites

Terminated6Sites

王照元
Kaohsiung Municipal Gangshan Hospital

未分科

邱昌芳
China Medical University Hospital-Taipei

未分科

2016-03-20 - 2019-01-20

Phase II

A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed alone in Patients with Heregulin Positive, Locally Advanced or Metastatic, Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    MM-121

Participate Sites
4Sites

Terminated3Sites

夏德椿
China Medical University Hospital-Taipei

未分科

2017-07-01 - 2020-03-31

Phase II

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE).

  • Condition/Disease

    Metastatic Triple Negative Breast Cancer

  • Test Drug

    Olaparib (AZD2281), AZD6738 and AZD1775

Participate Sites
10Sites

Terminated9Sites

趙祖怡
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of General Internal Medicine

陳訓徹
Linkou Chang Gung Medical Foundation

2019-04-11 - 2021-09-30

Phase II

A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression.

  • Condition/Disease

    Gastric Cancer / Gastro-esophageal Junction (GEJ) Cancer

  • Test Drug

    Zolbetuximab (IMAB362)

Participate Sites
3Sites

Recruiting2Sites

白禮源
China Medical University Hospital-Taipei

未分科

2017-03-17 - 2023-04-17

Phase III

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    ASP2215

Participate Sites
4Sites

Recruiting3Sites

1 18 19 20 21 22 27
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB